Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elan

- PMLiVE

Perrigo warming to Mylan – at the right price

Perrigo has already rejected three prior bids

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

Mylan pulls no punches in rejecting Teva takeover

Firm calls Israeli generics giant’s credibility into question

- PMLiVE

Teva circling as Perrigo rejects second Mylan offer

Claims latest offer is lower than a recent informal bid

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

- PMLiVE

Mylan swoops in on Perrigo with $30bn offer

Comes amid a swarm of deals for both companies in recent years

- PMLiVE

Perrigo expands consumer health with €3.6bn Omega purchase

Follows takeover of Elan last year

- PMLiVE

Mylan buys US rights to blood clot drug

$300m deal to acquire Arixtra from South Africa’s Aspen

- PMLiVE

Mylan buys Abbott’s non-US generics in $5.3bn deal

Lower tax rate drives bid to create new firm based in Netherlands

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

AZ sues to block generic saxagliptin from Mylan

Attempt to protect diabetes treatments Onglyza and Kombiglyze XR

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links